Search alternatives:
largest decrease » largest decreases (Expand Search), larger decrease (Expand Search), marked decrease (Expand Search)
rate increased » greater increase (Expand Search)
Showing 901 - 920 results of 1,199 for search 'ct ((largest decrease) OR (rate increased))', query time: 0.23s Refine Results
  1. 901
    Table_1_Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial.docx

    Table_1_Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results... by Yuping Yin (3617510)

    Published 2022
    “…The 1-year overall survival (OS) rate was 91.4% and the 1-year recurrence-free survival (RFS) rate was 90.0%. …”
    Save to List
    Saved in:
  2. 902
    Image_1_Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial.tif

    Image_1_Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results... by Yuping Yin (3617510)

    Published 2022
    “…The 1-year overall survival (OS) rate was 91.4% and the 1-year recurrence-free survival (RFS) rate was 90.0%. …”
    Save to List
    Saved in:
  3. 903
    Image_3_Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial.tif

    Image_3_Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results... by Yuping Yin (3617510)

    Published 2022
    “…The 1-year overall survival (OS) rate was 91.4% and the 1-year recurrence-free survival (RFS) rate was 90.0%. …”
    Save to List
    Saved in:
  4. 904
    Image_1_Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial.tif

    Image_1_Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results... by Yuping Yin (3617510)

    Published 2022
    “…The 1-year overall survival (OS) rate was 91.4% and the 1-year recurrence-free survival (RFS) rate was 90.0%. …”
    Save to List
    Saved in:
  5. 905
    Image_2_Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial.tif

    Image_2_Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results... by Yuping Yin (3617510)

    Published 2022
    “…The 1-year overall survival (OS) rate was 91.4% and the 1-year recurrence-free survival (RFS) rate was 90.0%. …”
    Save to List
    Saved in:
  6. 906
    Image_3_Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial.tif

    Image_3_Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results... by Yuping Yin (3617510)

    Published 2022
    “…The 1-year overall survival (OS) rate was 91.4% and the 1-year recurrence-free survival (RFS) rate was 90.0%. …”
    Save to List
    Saved in:
  7. 907
    Table_1_Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial.docx

    Table_1_Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results... by Yuping Yin (3617510)

    Published 2022
    “…The 1-year overall survival (OS) rate was 91.4% and the 1-year recurrence-free survival (RFS) rate was 90.0%. …”
    Save to List
    Saved in:
  8. 908
    Image_2_Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial.tif

    Image_2_Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results... by Yuping Yin (3617510)

    Published 2022
    “…The 1-year overall survival (OS) rate was 91.4% and the 1-year recurrence-free survival (RFS) rate was 90.0%. …”
    Save to List
    Saved in:
  9. 909
    Data_Sheet_1_Prognostic Significance of Preoperative Sarcopenia in Patients With Gastric Cancer Liver Metastases Receiving Hepatectomy.CSV

    Data_Sheet_1_Prognostic Significance of Preoperative Sarcopenia in Patients With Gastric Cancer Liver Metastases Receiving Hepatectomy.CSV by Jianping Xiong (3690322)

    Published 2022
    “…Background<p>The present work focused on assessing the role of computed tomography (CT)-determined sarcopenia in the prognosis of patients with gastric cancer liver metastases (GCLM) receiving hepatectomy.…”
    Save to List
    Saved in:
  10. 910
    Data_Sheet_2_Prognostic Significance of Preoperative Sarcopenia in Patients With Gastric Cancer Liver Metastases Receiving Hepatectomy.CSV

    Data_Sheet_2_Prognostic Significance of Preoperative Sarcopenia in Patients With Gastric Cancer Liver Metastases Receiving Hepatectomy.CSV by Jianping Xiong (3690322)

    Published 2022
    “…Background<p>The present work focused on assessing the role of computed tomography (CT)-determined sarcopenia in the prognosis of patients with gastric cancer liver metastases (GCLM) receiving hepatectomy.…”
    Save to List
    Saved in:
  11. 911
    CARDIOVASCULAR AND STRENGTH ADAPTATIONS IN CONCURRENT TRAINING IN HYPERTENSIVE WOMEN

    CARDIOVASCULAR AND STRENGTH ADAPTATIONS IN CONCURRENT TRAINING IN HYPERTENSIVE WOMEN by Ayrton Moraes Ramos (7476248)

    Published 2019
    “…Muscle strength (8-RM), systolic and diastolic blood pressure, heart rate, and double product were assessed pre- and post-exercise. …”
    Save to List
    Saved in:
  12. 912
    DataSheet_1_Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis.pdf

    DataSheet_1_Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis.p... by Hao Qin (113159)

    Published 2023
    “…</p>Conclusion<p>The pooled correlations indicated that the neoadjuvant immunotherapy (both nICT and nICRT) could significantly increase the rates of pCR and MPR, compared with routine neoadjuvant therapy (both nCT and nCRT) in the treatment of locally advanced EC. …”
    Save to List
    Saved in:
  13. 913
    DataSheet_1_Gross Tumor Volume Predicts Survival and Pathological Complete Response of Locally Advanced Esophageal Cancer After Neoadjuvant Chemoradiotherapy.docx

    DataSheet_1_Gross Tumor Volume Predicts Survival and Pathological Complete Response of Locally Advanced Esophageal Cancer After Neoadjuvant Chemoradiotherapy.docx by Rong Wang (59795)

    Published 2022
    “…</p>Methods<p>We reviewed the data of 72 patients with cT2-4N0-3M0 EC who underwent neo-CRT at our hospital. …”
    Save to List
    Saved in:
  14. 914
    Table_2_Semantic and Geographical Analysis of COVID-19 Trials Reveals a Fragmented Clinical Research Landscape Likely to Impair Informativeness.XLSX

    Table_2_Semantic and Geographical Analysis of COVID-19 Trials Reveals a Fragmented Clinical Research Landscape Likely to Impair Informativeness.XLSX by Giulia Tini (9039167)

    Published 2020
    “…</p><p>Methods: We developed an online repository (COVID Trial Monitor) to analyze in real time the growth rate, geographical distribution, and characteristics of COVID-19 related trials. …”
    Save to List
    Saved in:
  15. 915
    Data_Sheet_1_Semantic and Geographical Analysis of COVID-19 Trials Reveals a Fragmented Clinical Research Landscape Likely to Impair Informativeness.docx

    Data_Sheet_1_Semantic and Geographical Analysis of COVID-19 Trials Reveals a Fragmented Clinical Research Landscape Likely to Impair Informativeness.docx by Giulia Tini (9039167)

    Published 2020
    “…</p><p>Methods: We developed an online repository (COVID Trial Monitor) to analyze in real time the growth rate, geographical distribution, and characteristics of COVID-19 related trials. …”
    Save to List
    Saved in:
  16. 916
    Table 1_OligoDOMTM: a T-cell response-enhancing platform applied to cancer immunotherapy.pdf

    Table 1_OligoDOMTM: a T-cell response-enhancing platform applied to cancer immunotherapy.pdf by Judith Del Campo (10953087)

    Published 2025
    “…Specific T-cell responses against four tumor models (MC38, CT26, TC-1, B16-OVA) were measured using ELISpot in naïve mice. …”
    Save to List
    Saved in:
  17. 917
    Image1_The rapid inhibition of B-cell activation markers by belimumab was associated with disease control in systemic lupus erythematosus patients.JPEG

    Image1_The rapid inhibition of B-cell activation markers by belimumab was associated with disease control in systemic lupus erythematosus patients.JPEG by Jing Wang (6206297)

    Published 2023
    “…</p><p>Clinical Trial Registration:https://www.clinicaltrials.gov/ct2/show/NCT04893161?term=NCT04893161&draw=2&rank=1; identifier: NCT04893161.…”
    Save to List
    Saved in:
  18. 918
    Table_1_Whole-Body MRI Is an Effective Imaging Modality for Hematological Malignancy Treatment Response Assessment: A Systematic Review and Meta-Analysis.docx

    Table_1_Whole-Body MRI Is an Effective Imaging Modality for Hematological Malignancy Treatment Response Assessment: A Systematic Review and Meta-Analysis.docx by Guisen Lin (8145510)

    Published 2022
    “…The adding of WB-DWI is strongly associated with increased sensitivity.</p>…”
    Save to List
    Saved in:
  19. 919
    Table1_The rapid inhibition of B-cell activation markers by belimumab was associated with disease control in systemic lupus erythematosus patients.DOCX

    Table1_The rapid inhibition of B-cell activation markers by belimumab was associated with disease control in systemic lupus erythematosus patients.DOCX by Jing Wang (6206297)

    Published 2023
    “…</p><p>Clinical Trial Registration:https://www.clinicaltrials.gov/ct2/show/NCT04893161?term=NCT04893161&draw=2&rank=1; identifier: NCT04893161.…”
    Save to List
    Saved in:
  20. 920
    Table_4_Semantic and Geographical Analysis of COVID-19 Trials Reveals a Fragmented Clinical Research Landscape Likely to Impair Informativeness.XLSX

    Table_4_Semantic and Geographical Analysis of COVID-19 Trials Reveals a Fragmented Clinical Research Landscape Likely to Impair Informativeness.XLSX by Giulia Tini (9039167)

    Published 2020
    “…</p><p>Methods: We developed an online repository (COVID Trial Monitor) to analyze in real time the growth rate, geographical distribution, and characteristics of COVID-19 related trials. …”
    Save to List
    Saved in:

Search Tools: